Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · Real-Time Price · USD
2.610
-0.050 (-1.88%)
At close: Nov 21, 2024, 4:00 PM
2.550
-0.060 (-2.30%)
After-hours: Nov 21, 2024, 5:16 PM EST

Company Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.

It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Aerovate Therapeutics, Inc.
Aerovate Therapeutics logo
Country United States
Founded 2018
IPO Date Jun 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 51
CEO Timothy Noyes

Contact Details

Address:
930 Winter Street, Suite M-500
Waltham, Massachusetts 02451
United States
Phone 617 443 2400
Website aerovatetx.com

Stock Details

Ticker Symbol AVTE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $14.00
CIK Code 0001798749
CUSIP Number 008064107
ISIN Number US0080641071
Employer ID 83-1377888
SIC Code 2834

Key Executives

Name Position
Timothy P. Noyes M.B.A. Chief Executive Officer and Director
George A. Eldridge Chief Financial Officer and Treasurer
Dr. Benjamin T. Dake Ph.D. Founder, President, Chief Operating Officer and Secretary
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S Chief Scientific Officer
Hunter Gillies M.D. Chief Medical Officer
Donna Dea Head of Regulatory Affairs
Susan Fischer Executive Vice President of Development Operations
Stephen K. Yu Senior Vice President of Quality
Dr. Sanjeev Khindri Executive Vice President of Clinical Development
Dr. Cheryl Lassen BSc., M.D., MBBCh Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Nov 18, 2024 425 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 10-Q Quarterly Report
Oct 31, 2024 425 Filing
Oct 31, 2024 425 Filing
Oct 31, 2024 425 Filing
Oct 31, 2024 425 Filing
Oct 31, 2024 425 Filing
Oct 31, 2024 8-K Current Report
Oct 17, 2024 8-K Current Report